May 22, 2024 10:41 AM EDT

Dyne's $305M offering; Nanobiotix delays Ph2 readout

ENDPOINTS

Dyne Therapeutics expects to net $305M in stock sale: The company on Monday dropped updated stock-moving results for its myotonic dystrophy type …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dyne's $305M offering; Nanobiotix delays Ph2 readout

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dyne's $305M of­fer­ing; Nanobi­otix de­lays Ph2 read­out

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Dyne's $305M offering; Nanobiotix delays Ph2 readout